Clinical Trial Update: MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer [Phase 1]

View source ↗

Summary

A Phase 1 trial from Emory University is evaluating the combination of MRX-2843 and osimertinib in adults with advanced EGFR-mutant non-small cell lung cancer; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• MRX-2843 (mrx-2843)
• TAGRISSO (osimertinib)

Snippet

Sponsor: Emory University | Conditions: Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma | Phase 1 | Status: RECRUITING